Cerus Corporation (CERS)

-4.36% (1D)

Market Cap	264.75M
Revenue (ttm)	180.27M
Net Income (ttm)	-20.92M
Shares Out	185.79M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,256,515
Open	1.470
Previous Close	1.490
Day's Range	1.400 - 1.475
52-Week Range	1.380 - 2.540
Beta	1.56
Analysts	Strong Buy
Price Target	3.50 (+145.61%)
Earnings Date	May 1, 2025

About CERS

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jan 30, 1997
• Employees: 630
• Stock Exchange: NASDAQ
• Ticker Symbol: CERS
• Website: https://www.cerus.com

Financial Performance

In 2024, Cerus's revenue was $180.27 million, an increase of 15.29% compared to the previous year's $156.37 million. Losses were -$20.92 million, -44.20% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for CERS stock is "Strong Buy." The 12-month stock price forecast is $3.5, which is an increase of 145.61% from the latest price.

Price Target

$3.5

(145.61% upside)

Analyst Consensus: Strong Buy